Market Research Report
Global Glioma Therapeutics Market 2019-2023
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||762865|
|Published||Content info||114 Pages
Delivery time: 1-2 business days
|Global Glioma Therapeutics Market 2019-2023|
|Published: December 14, 2018||Content info: 114 Pages||
Strategic alliances to drive growth in the market. Pharmaceutical companies are collaborating to develop medications for the treatment of glioma. These alliances can enhance R&D activities for new drugs for the treatment of glioma. Technavio' s analysts have predicted that the glioma therapeutics market will register a CAGR of more than 9% by 2023.
As the market is currently experiencing an acute lack of approved therapies, these late-stage pipeline molecules can tap into this unmet demand from the glioma patient pool. Once these molecules are launched during the forecast period, the global glioma therapeutics market should observe strong value growth from these newly launched therapeutics.
Despite the availability of medications for the treatment of the glioma, there are several alternative procedures. The high cost, side effects, and long duration of treatment with the available medications are increasing patients' inclination toward the surgical and radiation treatment options.
For the detailed list of factors that will drive and challenge the growth of the glioma therapeutics market during the 2019-2023, view our report.
The market appears to be fragmented and with the presence of several companies including NextSource Biotechnology and Novartis the competitive environment is quite intense. Factors such as the expected approval of late-stage pipeline molecules and the strategic alliances, will provide considerable growth opportunities to glioma therapeutics manufactures. F. Hoffmann-La Roche, Merck Sharp & Dohme, Mylan, NextSource Biotechnology, and Novartis are some of the major companies covered in this report.